Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Almirall SA
Agios’s divestment of its oncology pipeline and commercial operations provided a rare case where all parties appeared satisfied. In many other cases, there are winners and losers.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
With its lead cannabinoid product Epidiolex continuing to advance, the London-headquartered, NASDAQ-listed firm has begun late-stage trials in the US with nabiximols, which looks likely to become its second approved drug.
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.